METRIC 3期研究:BRAF V600 E/K突变晚期或转移性黑色素瘤患者的5年结局
METRIC 3期开放标签研究纳入322例BRAF V600 E/K突变转移性黑色素瘤患者,按2:1随机接受曲美替尼(n=214)或化疗(n=108)。曲美替尼组中位无进展生存期4.9个月 vs 化疗组1.5个月(HR 0.54,95%CI 0.41-0.73);5年总生存率曲美替尼组13.3% vs 化疗组17.0%。长期使用曲美替尼未出现新的或非预期不良事件。
要点
- 曲美替尼组中位PFS 4.9个月 vs 化疗组1.5个月,HR 0.54(95%CI 0.41-0.73)。
- 5年总生存率曲美替尼组13.3% vs 化疗组17.0%。
- 长期使用曲美替尼未报告新的或非预期不良事件。
核心结论
- 5年随访显示BRAF V600 E/K突变转移性黑色素瘤患者长期使用曲美替尼可行,未出现新的或非预期不良事件,部分患者从曲美替尼单药治疗中获得长期生存获益。
研究设计与样本
- METRIC(TMT212A2301)为开放标签3期研究,纳入322例BRAF V600 E/K突变不可切除或转移性皮肤黑色素瘤患者,按2:1随机接受曲美替尼(2 mg口服,每日一次;n=214)或化疗(达卡巴嗪1000 mg/m2或紫杉醇175 mg/m2静脉给药,每3周一次;n=108)。
- 化疗组进展的患者允许交叉接受曲美替尼治疗。
- 本次报告5年疗效与安全性分析结果。
主要发现
- 曲美替尼组中位PFS为4.9个月 vs 化疗组1.5个月(HR 0.54;95%CI 0.41-0.73)。
- 1年总生存率曲美替尼组60.9% vs 化疗组49.6%,2年总生存率曲美替尼组32.0% vs 化疗组29.4%,5年总生存率曲美替尼组13.3% vs 化疗组17.0%。
- 化疗组大多数患者(n=70,65%)在治疗早期交叉至曲美替尼组。
- 未报告非预期不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary findings from the METRIC (TMT212A2301) study demonstrated that trametinib improved progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with unresectable or metastatic cutaneous melanoma with a BRAF V600 E/K mutation. However, clinical data characterising the long-term use of these therapies in combination with BRAF inhibitors or as monotherapies are limited. METHODS: In this open-label, phase 3 study, 322 patients with BRAF V600 E/K-mutant metastatic melanoma were randomised in a 2:1 ratio to receive trametinib (2 mg orally, once daily; n = 214) or chemotherapy (dacarbazine [1000 mg/m2] or paclitaxel [175 mg/m2] intravenously, every 3 weeks; n = 108). Patients who progressed on chemotherapy were allowed to cross over and receive trametinib. Five-year results of efficacy and safety analyses are reported. RESULTS: The median PFS was 4.9 months in the trametinib arm versus 1.5 months in the chemotherapy arm (hazard ratio, 0.54; 95% confidence interval, 0.41-0.73). Landmark OS rates for trametinib versus chemotherapy arms at 1 year, 2 years and 5 years were 60.9% versus 49.6%, 32.0% versus 29.4% and 13.3% versus 17.0%, respectively. Most patients (n = 70 [65%]) from the chemotherapy arm crossed over to the trametinib arm early in their treatment. No unexpected adverse events were reported. CONCLUSIONS: This 5-year follow-up of patients with BRAF V600 E/K-mutant metastatic melanoma on a targeted therapy demonstrates that long-term use of trametinib is possible with no new or unexpected adverse events. Some patients experienced long-term survival benefit with trametinib monotherapy (METRIC ClinicalTrials.gov number, NCT01245062.).
引用
- Robert C, Flaherty K, Nathan P, et al. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. Eur J Cancer. 2019. PMID: 30690294. doi:10.1016/j.ejca.2018.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。